Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC

Trial Profile

An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; ALT 803 (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; Paclitaxel (Primary) ; Doxorubicin
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 10 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment as trial not initiated.
    • 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
    • 05 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top